SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for ORYZF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical SG&A Expense (TTM) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 3.389M
March 31, 2026 2.603M
December 31, 2025 1.972M
September 30, 2025 1.326M
June 30, 2025 0.8694M
March 31, 2025 1.351M
December 31, 2024 1.092M
September 30, 2024 1.339M
June 30, 2024 1.152M
March 31, 2024 0.8722M
December 31, 2023 1.227M
September 30, 2023 1.462M
June 30, 2023 1.797M
March 31, 2023 2.290M
December 31, 2022 2.529M
September 30, 2022 3.015M
June 30, 2022 3.340M
Date Value
March 31, 2022 2.851M
September 30, 2021 2.293M
June 30, 2021 1.469M
March 31, 2021 0.9133M
December 31, 2020 0.7822M
September 30, 2020 0.679M
June 30, 2020 0.559M
March 31, 2020 0.7529M
December 31, 2019 0.7964M
September 30, 2019 0.687M
June 30, 2019 0.745M
March 31, 2019 0.5029M
December 31, 2018 0.2947M
September 30, 2018 1.690M
June 30, 2018 1.506M
March 31, 2018 1.417M
March 31, 2016 1.396M

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Pharma Mar SA 73.98M
Grifols SA 1.318B
ACADIA Pharmaceuticals, Inc. 620.29M
Alkermes Plc 841.17M
Alnylam Pharmaceuticals, Inc. 1.318B